Literature DB >> 10851412

Lymph-node staining with activated carbon CH40: a new method for axillary lymph-node dissection in breast cancer.

T Yokota1, T Saito, Y Narushima, K Iwamoto, M Iizuka, A Hagiwara, K Sawai, S Kikuchi, Y Kunii, H Yamauchi.   

Abstract

OBJECTIVE: To demonstrate the usefulness of activated carbon particles (CH40) as a vital staining dye for visualizing lymphatic vessels and lymph nodes in breast cancer.
DESIGN: A retrospective evaluation.
SETTING: Department of Surgery in Sendai National Hospital, Japan, a 716-bed teaching hospital.
METHODS: To identify as many lymph nodes as possible in the axillary fat, by which we might decrease the possibility of the presence of undetected metastatic nodes, an emulsion of activated carbon particles (CH40) was injected into the centre of the mammary gland, close to the tumour site, 3 days before radical surgery. MAIN OUTCOME MEASURE: The number of lymph nodes found by the traditional method and by the CH40-injection method were recorded.
RESULTS: After injection, the CH40 was readily adsorbed into regional lymphatics and streamed along with the lymph flow to blacken regional lymph nodes. The CH40-guided method increased the mean number of nodes per case found in the axilla from 8.4, by the traditional method, to 14.0 nodes per case.
CONCLUSIONS: The use of the CH40 technique has two technical advantages; one is that it allows surgeons to locate the blackened lymph nodes at the time of surgery and the other is that it allows pathologists to look for the nodes in fatty tissue. Lymph-node dissection with the aid of activated carbon particles is inexpensive, easy to perform and enables the smallest lymph nodes to be easily recognized. CH40 is the technique of choice for the detection of axillary lymph nodes in cases where the number of lymph nodes detected by the traditional method is too small for accurate surgery. In conclusion, the present study demonstrates that CH40 could be an appropriate tool for more accurate staging of breast cancer axillary specimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851412      PMCID: PMC3695160     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  6 in total

1.  A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer.

Authors:  Qian Yang; Xiao-dong Wang; Jie Chen; Chun-xiang Tian; Hong-jiang Li; Yu-Juan Chen; Qing Lv
Journal:  Tumour Biol       Date:  2012-09-05

2.  Clinical application of nano-carbon to improve the accuracy of lymph node staging in patients with advanced gastric cancer receiving neoadjuvant chemotherapy: a prospective randomized controlled trial.

Authors:  Peigang Yang; Yuan Tian; Bibo Tan; Pingan Ding; Honghai Guo; Yang Liu; Zhidong Zhang; Yong Li; Qun Zhao
Journal:  J Gastrointest Oncol       Date:  2021-10

3.  CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.

Authors:  Shuang Jiang; Xiaobo Wang; Zhiran Zhang; Lan Sun; Yunzhu Pu; Hongjuan Yao; Jingcao Li; Yan Liu; Yingge Zhang; Weijing Zhang
Journal:  Int J Nanomedicine       Date:  2016-11-02

4.  The Enhanced and Tunable Sustained Release of Pesticides Using Activated Carbon as a Carrier.

Authors:  Jun Yang; Wanyu Zang; Zheng Zhang; Peng Wang; Qing Yang
Journal:  Materials (Basel)       Date:  2019-12-03       Impact factor: 3.623

5.  Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer.

Authors:  Jianghao Chen; Ling Wang; Qing Yao; Rui Ling; Kaizong Li; Hui Wang
Journal:  Breast Cancer Res       Date:  2004-06-17       Impact factor: 6.466

6.  Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.

Authors:  Junze Du; Yongsong Zhang; Jia Ming; Jing Liu; Ling Zhong; Quankun Liang; Linjun Fan; Jun Jiang
Journal:  World J Surg Oncol       Date:  2016-06-22       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.